Unknown

Dataset Information

0

Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-?1 Signaling Pathway.


ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a fatal and age-related pulmonary disease. Nintedanib is a receptor tyrosine kinase inhibitor, and one of the only two listed drugs against IPF. Regorafenib is a novel, orally active, multi-kinase inhibitor that has similar targets to nintedanib and is applied to treat colorectal cancer and gastrointestinal stromal tumors in patients. In this study, we first identified that regorafenib could alleviate bleomycin-induced pulmonary fibrosis in mice. The in vivo experiments indicated that regorafenib suppresses collagen accumulation and myofibroblast activation. Further in vitro mechanism studies showed that regorafenib inhibits the activation and migration of myofibroblasts and extracellular matrix production, mainly through suppressing the transforming growth factor (TGF)-?1/Smad and non-Smad signaling pathways. In vitro studies have also indicated that regorafenib could augment autophagy in myofibroblasts by suppressing TGF-?1/mTOR (mechanistic target of rapamycin) signaling, and could promote apoptosis in myofibroblasts. In conclusion, regorafenib attenuates bleomycin-induced pulmonary fibrosis by suppressing the TGF-?1 signaling pathway.

SUBMITTER: Li X 

PROVIDER: S-EPMC7922359 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway.

Li Xiaohe X   Ma Ling L   Huang Kai K   Wei Yuli Y   Long Shida S   Liu Qinyi Q   Zhang Deqiang D   Wu Shuyang S   Wang Wenrui W   Yang Guang G   Zhou Honggang H   Yang Cheng C  

International journal of molecular sciences 20210217 4


Idiopathic pulmonary fibrosis (IPF) is a fatal and age-related pulmonary disease. Nintedanib is a receptor tyrosine kinase inhibitor, and one of the only two listed drugs against IPF. Regorafenib is a novel, orally active, multi-kinase inhibitor that has similar targets to nintedanib and is applied to treat colorectal cancer and gastrointestinal stromal tumors in patients. In this study, we first identified that regorafenib could alleviate bleomycin-induced pulmonary fibrosis in mice. The in viv  ...[more]

Similar Datasets

| S-EPMC8126120 | biostudies-literature
| S-EPMC8347567 | biostudies-literature
| S-EPMC8393190 | biostudies-literature
| S-EPMC6647111 | biostudies-literature
| S-EPMC6926420 | biostudies-literature
| S-EPMC6511757 | biostudies-literature
| S-EPMC5855696 | biostudies-literature
| S-EPMC8395032 | biostudies-literature
| S-EPMC8435416 | biostudies-literature
| S-EPMC4856290 | biostudies-literature